Shannon L. M. Dahl

Readily Available Tissue-Engineered Vascular Grafts

Nonimmunogenic, tissue-engineered vascular grafts stored long-term maintain their patency, strength, and function after transplant in large-animal models. Grow Your Own Blood Vessels Growing your own vegetables may be a well-established approach for a healthier life, but growing blood vessels for surgical transplantation is a more unusual pastime. But the idea of growing a readily available supply of blood vessels for surgical transplant into patients requiring, for example, a cardiac bypass or dialysis is not as far-fetched as it sounds. Although a patient’s own blood vessels can sometimes be used for the graft, often this is not possible. Engineered autologous blood vessels can be grown from endothelial cells taken from the patient and cultured on scaffolds, but this process takes 9 months or more, and often the patients cannot wait that long for surgery. Enter Dahl and her team with a new approach that provides readily available, off-the-shelf vascular grafts that retain their strength and patency during long-term storage and function successfully after vascular surgery in baboon and dog animal models. The authors grew their human vascular grafts by culturing smooth muscle cells from human cadavers (that is, allogeneic cells) on tubular scaffolds made from a biodegradable polymer called polyglycolic acid (PGA). The smooth muscle cells produced collagen and other molecules that formed an extracellular matrix. When the scaffold degraded, fully formed vascular grafts were left behind. The investigators then stripped the cells from the grafts, using detergent to make sure the grafts would not elicit an immune response when transplanted. These human vascular grafts were 6 mm or greater in diameter and retained their strength, elasticity, and patency even after storage in phosphate-buffered saline solution for a year. The human vascular grafts were tested in a baboon model of arteriovenous bypass in which the graft formed a direct conduit between an artery and a vein (an approach that enables human patients with kidney disease to undergo dialysis). The authors showed that the grafts in baboons restored blood flow and retained their patency and strength for up to 6 months. When the grafts were removed and examined histologically, they did not show evidence of fibrosis, calcification, or thickening of the vessel wall intima. But the authors wanted to test engineered vascular grafts with smaller diameters, which are often plagued by thrombi (blood clots) after transplant. To do this, they turned to a dog model of peripheral and coronary artery bypass, surgeries that require smaller-diameter vascular grafts. Using dog smooth muscle cells cultured on PGA scaffolds, they created canine vascular grafts with small diameters (3 to 4 mm). They then seeded these grafts with endothelial cells (from the dogs due to be recipients) because an endothelial cell lining helps to prevent blood clot formation. Using the engineered grafts, the investigators then conducted either peripheral or coronary artery bypass in the dog recipients and showed that they functioned effectively for at least 1 month. Together, these results demonstrate that durable vascular grafts derived from allogeneic donors and rendered nonimmunogenic by removal of donor cells are suitable for surgical transplant. The added advantage of being able to store these off-the-shelf vascular grafts long-term in a simple saline solution means that these can be made ahead of time and then are ready to go whenever they are needed. Growing blood vessels for a healthier life is as real as the home-grown asparagus in your garden. Autologous or synthetic vascular grafts are used routinely for providing access in hemodialysis or for arterial bypass in patients with cardiovascular disease. However, some patients either lack suitable autologous tissue or cannot receive synthetic grafts. Such patients could benefit from a vascular graft produced by tissue engineering. Here, we engineer vascular grafts using human allogeneic or canine smooth muscle cells grown on a tubular polyglycolic acid scaffold. Cellular material was removed with detergents to render the grafts nonimmunogenic. Mechanical properties of the human vascular grafts were similar to native human blood vessels, and the grafts could withstand long-term storage at 4°C. Human engineered grafts were tested in a baboon model of arteriovenous access for hemodialysis. Canine grafts were tested in a dog model of peripheral and coronary artery bypass. Grafts demonstrated excellent patency and resisted dilatation, calcification, and intimal hyperplasia. Such tissue-engineered vascular grafts may provide a readily available option for patients without suitable autologous tissue or for those who are not candidates for synthetic grafts.

Blood vessels engineered from human cells

Tissue engineering has made considerable progress in the past decade, but advances have stopped short of clinical application for most tissues. We postulated that an obstacle in engineering human tissues is the limited replicative capacity of adult somatic cells. To test this hypothesis, the effectiveness of telomerase expression to extend cellular lifespan was assessed in a model of human vascular tissue engineering. Telomerase expression in vascular cells isolated from elderly patients enabled the successful culture of engineered autologous blood vessels. Engineered vessels may one day provide a source of bypass conduit for patients with atherosclerotic disease.

Mechanical Properties and Compositions of Tissue Engineered and Native Arteries

With the goal of mimicking the mechanical properties of a given native tissue, tissue engineers seek to culture replacement tissues with compositions similar to those of native tissues. In this report, differences between the mechanical properties of engineered arteries and native arteries were correlated with differences in tissue composition. Engineered arteries failed to match the strengths or compliances of native tissues. Lower strengths of engineered arteries resulted partially from inferior organization of collagen, but not from differences in collagen density. Furthermore, ultimate strengths of engineered vessels were significantly reduced by the presence of residual polyglycolic acid polymer fragments, which caused stress concentrations in the vessel wall. Lower compliances of engineered vessels resulted from minimal smooth muscle cell contractility and a lack of organized extracellular elastin. Organization of elastin and collagen in engineered arteries may have been partially hindered by high concentrations of sulfated glycosaminoglycans. Tissue engineers should continue to regulate cell phenotype and promote synthesis of proteins that are known to dominate the mechanical properties of the associated native tissue. However, we should also be aware of the potential negative impacts of polymer fragments and glycosaminoglycans on the mechanical properties of engineered tissues.

Effects of copper and cross-linking on the extracellular matrix of tissue-engineered arteries.

In many cases, the mechanical strengths of tissue-engineered arteries do not match the mechanical strengths of native arteries. Ultimate arterial strength is primarily dictated by collagen in the extracellular matrix, but collagen in engineered arteries is not as dense, as organized, or as mature as collagen in native arteries. One step in the maturation process of collagen is the formation of hydroxylysyl pyridinoline (HP) cross-links between and within collagen molecules. HP cross-link formation, which is triggered by the copper-activated enzyme lysyl oxidase, greatly increases collagen fibril stability and enhances tissue strength. Increased cross-link formation, in addition to increased collagen production, may yield a stronger engineered tissue. In this article, the effect of increasing culture medium copper ion concentration on engineered arterial tissue composition and mechanics was investigated. Engineered vessels grown in low copper ion concentrations for the first 4 weeks of culture, followed by higher copper ion concentrations for the last 3 weeks of culture, had significantly elevated levels of cross-link formation compared to those grown in low copper ion concentrations. In contrast, vessels grown in high copper ion concentrations throughout culture failed to develop higher collagen cross-link densities than those grown in low copper ion concentrations. Although the additional cross-linking of collagen in engineered vessels may provide collagen fibril stability and resistance to proteolysis, it failed to enhance global tissue strength.

An Ultrastructural Analysis of Collagen in Tissue Engineered Arteries

Collagen is the structural molecule that is most correlated with strength in blood vessels. In this study, we compared the properties of collagen in engineered and native blood vessels. Transmission electron microscopy (TEM) was used to image sections of engineered and native arteries. Band periodicities of engineered and native collagen fibrils indicated that spacing between collagen molecules was similar in engineered and native tissues. Engineered arteries, however, had thinner collagen fibrils and fibers than native arteries. Further, collagen fibrils were more loosely packed within collagen fibers in engineered arteries than in native arteries. The sensitivity of TEM analysis allowed measurement of the relative frequency of observation for alignment of collagen. These observations showed that collagen in both engineered and native arteries was aligned circumferentially, helically, and axially, but that engineered arteries had less circumferential collagen and more axial collagen than native arteries. Given that collagen is primarily responsible for dictating the ultimate mechanical properties of arterial tissue, future efforts should focus on using relative frequency of observation for alignment of collagen as a descriptive input for models of the mechanical properties of engineered or native tissues.

What Is the Greatest Regulatory Challenge in the Translation of Biomaterials to the Clinic

Leaders in the field comment on what they perceive to be the greatest barriers to biomaterial translation. Leaders in the field comment on what they perceive to be the greatest barriers to biomaterial translation.

Effects of Mechanical Stretch on Collagen and Cross-Linking in Engineered Blood Vessels

It has been shown that mechanical stimulation affects the physical properties of multiple types of engineered tissues. However, the optimum regimen for applying cyclic radial stretch to engineered arteries is not well understood. To this end, the effect of mechanical stretch on the development of engineered blood vessels was analyzed in constructs grown from porcine vascular smooth muscle cells. Cyclic radial distension was applied during vessel culture at three rates: 0 beats per minute (bpm), 90 bpm, and 165 bpm. At the end of the 7-week culture period, harvested vessels were analyzed with respect to physical characteristics. Importantly, mechanical stretch at 165 bpm resulted in a significant increase in rupture strength in engineered constructs over nonstretched controls. Stress–strain data and maximal elastic moduli from vessels grown at the three stretch rates indicate enhanced physical properties with increasing pulse rate. In order to investigate the role of collagen cross-linking in the improved mechanical characteristics, collagen cross-link density was quantified by HPLC. Vessels grown with mechanical stretch had somewhat more collagen and higher burst pressures than nonpulsed control vessels. Pulsation did not increase collagen cross-link density. Thus, increased wall thickness and somewhat elevated collagen concentrations, but not collagen cross-link density, appeared to be responsible for increased burst strength.

Arteriovenous Fistulae for Haemodialysis: A Systematic Review and Meta-analysis of Efficacy and Safety Outcomes

BACKGROUND Arteriovenous fistulae are the currently recommended gold standard vascular access modality for haemodialysis because of their prolonged patency, improved durability, and low risk of infection for those that mature. However, notable disadvantages are observed in terms of protracted maturation time, associated high rates of catheter use, and substantial abandonment rates. The aim of this study was to quantitatively summarize the outcomes of fistula patency, infection, maturation, and abandonment published in the scientific literature. METHODS This was a systematic review and meta-analyses of studies evaluating fistula outcomes. Literature searches were conducted in multiple databases to identify observational and interventional studies of mean fistula patency rates at 1 year, infection risk, maturation time, and abandonment. Digitisation software was used to simulate individual patient level data from Kaplan-Meier survival plots. RESULTS Over 8000 studies were reviewed, and from these, 318 studies were included comprising 62,712 accesses. For fistulas the primary unassisted, primary assisted, and secondary patency rates at one year were 64%, 73% and 79% respectively, however not all fistulas reported as patent could be confirmed as being clinically useful for dialysis (i.e. functional patency). For fistulas that were reported as mature, mean time to maturation was 3.5 months, however only 26% of created fistulas were reported as mature at 6 months and 21% of fistulas were abandoned without use. Overall risk of infection in fistula patients was 4.1% and the overall rate per 100 access days was 0.018. CONCLUSIONS Reported fistula patency rates may overstate their potential clinical utility when time to maturation, maturation rate, abandonment and infection are considered. Protracted maturation times, abandonment and infection all have a significant impact on evaluating the clinical utility of fistula creation. A rigorous and consistent set of outcomes definitions for hemodialysis access are necessary to clarify factors contributing to fistula success and the clinical consequence of fistula failure.